Login or sign up
For business

MicroPort CardioFlow

4.5· 8 reviews
Average ratingExcellent
4.5/ 5

Based on 8 reviews

563%
425%
313%
20%
10%
Ask AI

Questions about MicroPort CardioFlow

Based on 8 reviews, listing data and website checks · updated 4 days ago

What is MicroPort CardioFlow?

Shanghai MicroPort CardioFlow Medtech Co., Ltd. is a subsidiary of MicroPort Scientific Corporation founded in 2015 in Shanghai Zhangjiang Hi-Tech Park. The company provides advanced minimally invasive therapies for structural heart diseases and operates under the motto 'Focus, Innovation, and Globalization'.

What specific features does the VitaFlow Liberty® system include?

The company's website states that VitaFlow Liberty® is the world's only electrically retrievable transcatheter aortic valve system. This system features a self-expanding bovine pericardial valve and a dual-rail spiral innovative structure to reduce vascular complications.

How does the VitaFlow Liberty® Flex system handle complex anatomical challenges?

VitaFlow Liberty® Flex is described as the world's only 'true' coaxial controllable self-expanding TAVI delivery system. It allows for precise three-dimensional coaxial release through segmented bending techniques, even in extreme cases like cross-heart angles over 80 degrees.

What is the AnchorMan® system and where has it been recently implanted?

AnchorMan® is a left atrial appendage closure system that has completed its first commercial implantations in Portugal. The device features a semi-closed design that balances anchoring force with safety, according to Dr. João António Brum da Silveira.

What long-term safety and durability results were published for the VitaFlow® series?

The company's 10-year follow-up study data showed a re-operation rate of only 2.3% and a structural valve deterioration rate of 5.2%. These results were released during the Chengdu PCR-CIT 2026 conference by Professor Zhou Daxin and Professor Zhao Zhenggang.

Where has VitaFlow Liberty® recently achieved commercial success?

VitaFlow Liberty® completed its first commercial implantations in Austria, marking its expansion into European markets. The company has now covered core markets in China, Latin America, and Europe, with Portugal being the fifth European country served.

What is the scope of MicroPort CardioFlow's product pipeline and strategic goal?

The company's product portfolio includes 12 core product pipelines and over 40 global listed products covering pacemakers and ICDs. They aim to build a global leading integrated platform for structural heart disease, rhythm management, and heart failure management.

What does the Trustburn rating distribution indicate about customer satisfaction?

The Trustburn rating split shows 8 reviews with an average of 4.5 out of 5 stars. Most reviews praise the company's cutting-edge products, top-notch customer support, and informative website, with only one review giving a 3-star rating.

What regulatory milestones has the VitaFlow Liberty® system achieved?

The company's website mentions that the VitaFlow Liberty® system was approved by the NMPA in August 2021 and received EU CE certification in 2024. It also notes that the system entered the NMPA green channel in November 2018.

What are the stated mission and vision of MicroPort CardioFlow?

The company's mission is to provide affordable, true, good, and beautiful solutions to extend and reshape lives, aiming to help billions of people cross the 115-year life line healthily. Their vision is to become a leader in the heart failure diagnosis and treatment field.

What are the scale and reach of MicroPort CardioFlow's clinical operations?

The company has over 14,000 units of product clinical applications and operates in over 700 core hospitals. They hold more than 365 domestic and international authorized patents as of their latest reporting.

What clinical conditions does MicroPort CardioFlow target and what educational resources do they offer?

The company's clinical solutions address conditions such as aortic stenosis and atrial fibrillation. They also provide patient care resources including disease education and media center content to share updates with the public.

How does MicroPort CardioFlow leverage its rhythm management history?

The company's website states that they have over 60 years of professional accumulation in rhythm management, which they are integrating with their structural heart disease capabilities. They also mention their commitment to providing innovative heart failure full-cycle health management services.

What investor and recruitment resources are available on the company's website?

The company's website includes a section for investor relations, providing access to prospectus documents, announcements, and performance reports. They also offer a job application portal for prospective employees.

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About MicroPort CardioFlow

Shanghai MicroPort CardioFlow Medtech Co., Ltd. (MicroPort CardioFlow), founded 2015 in the Shanghai Zhangjiang Hi-Tech Park, is a subsidiary of MicroPort Scientific Corporation

MicroPort CardioFlow is dedicated to providing advanced minimally invasive therapies for structural heart diseases with its best-in-class capacities in R&D, manufacturing, marketing, and technical consulting services.

We believe in “Focus, Innovation, and Globalization”, and in accordance, we place the utmost importance on saving and improving quality of life for patients. Consequently, we constantly strive to bring the most innovative valvular disease treatment solutions to patients while also operating on a global vision to provide all patients and physicians with world-leading products that are superior, reliable, yet affordable.